Alvotech clinical trial results demonstrate curative equivalence between biosimilar candidate AVT06 and reference product Eylea® (aflibercept)
Confirmatory and efficacy clinical examination of AVT06, a biosimilar candidate for Eylea (aflibercept), achieved its number one endpoint in patients with a biosimilar to Eylea® (aflibercept).